慢性血栓栓塞性肺动脉高压的治疗进展  

Treatment progress on chronic thromboembolic pulmonary hypertension

作　　者：杨振文[1] 王宙明 李晟 邹珺 贺晓磊 Yang Zhenwen;Wang Zhouming;Li Sheng;Zou Jun;He Xiaolei(Department of Cardiology,Tianjin Medical University General Hospital,Tianjin 300052,China;MRL Global Medical Affairs,MSD China,Shanghai 200233,China)

机构地区：[1]天津医科大学总医院心内科,300052 [2]默沙东(中国)投资有限公司默沙东实验室医学事务部,上海200233

出　　处：《中国心血管杂志》2024年第3期278-282,共5页Chinese Journal of Cardiovascular Medicine

摘　　要：球囊肺血管成形术和药物是无法手术的慢性血栓栓塞性肺动脉高压(CTEPH)患者的主要治疗方案。在临床实践中,药物治疗是否比球囊肺血管成形术具有更好的获益-风险比,以及二者联用是否可增加临床疗效或改善安全性尚存争议。本文将系统阐述CTEPH的治疗进展,以指导临床管理。Balloon pulmonary angioplasty(BPA) and drugs are the two main treatment options for inoperable chronic thromboembolic pulmonary hypertension(CTEPH) patients.However,it is still unclear that whether the benefit-risk ratio of medical therapy outweighs the therapeutic potential of BPA and whether combination of treatments could improve the efficacy or safety.This article will comprehensively review the progress of treatment on inoperable CTEPH and guide clinical management.

关 键 词：慢性血栓栓塞性肺动脉高压 球囊肺血管成形术 肺动脉内膜剥脱术 利奥西呱 曲前列尼尔 马昔腾坦 

分 类 号：R544.1[医药卫生—心血管疾病]